GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans reduced its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 8.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,849 shares of the company’s stock after selling 12,043 shares during the quarter. Thrivent Financial for Lutherans’ holdings in GoodRx were worth $867,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of GDRX. Cornercap Investment Counsel Inc. increased its position in shares of GoodRx by 1.7% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock valued at $587,000 after purchasing an additional 1,266 shares during the last quarter. California State Teachers Retirement System raised its stake in GoodRx by 5.1% in the first quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock valued at $503,000 after buying an additional 3,444 shares in the last quarter. nVerses Capital LLC purchased a new stake in GoodRx during the 3rd quarter worth about $33,000. Plato Investment Management Ltd acquired a new position in shares of GoodRx during the 2nd quarter worth about $43,000. Finally, XTX Topco Ltd increased its holdings in shares of GoodRx by 42.4% in the 2nd quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock valued at $231,000 after acquiring an additional 8,801 shares during the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Citigroup decreased their target price on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Barclays cut their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. UBS Group decreased their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research note on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 target price on shares of GoodRx in a research report on Friday, August 16th. Finally, Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.86.

GoodRx Trading Down 0.6 %

NASDAQ:GDRX opened at $4.92 on Wednesday. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock’s 50 day simple moving average is $5.90 and its 200-day simple moving average is $7.21. GoodRx Holdings, Inc. has a 12-month low of $4.09 and a 12-month high of $9.26. The firm has a market cap of $1.88 billion, a P/E ratio of -164.00, a PEG ratio of 3.60 and a beta of 1.29.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.